Drugs that block NSD3 for aggressive lung cancer
Screening for inhibitors of NSD3 as a treatment for lung cancer
This project looks for small-molecule drugs that block a cancer-driving protein called NSD3 to help people with aggressive lung squamous cell carcinoma and other NSD3-driven cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11257333 on NIH RePORTER |
What this research studies
You would be hearing about lab work that searches large chemical libraries to find compounds that stop the NSD3 enzyme, which helps some lung cancers grow. The team uses a fluorescence polarization assay as a primary high-throughput screen, then confirms hits with follow-up biochemical and cell-based tests. Promising compounds will be tested in animal models to see if they slow tumor growth and to guide further drug development. All work is preclinical and focused on producing lead molecules that could move toward human testing.
Who could benefit from this research
Good fit: Future clinical trials would most likely enroll patients with lung squamous cell carcinoma or other cancers whose tumors show NSD3 amplification or overexpression.
Not a fit: People without NSD3-driven tumors or those needing immediate treatment should not expect direct benefit from this lab-based project right now.
Why it matters
Potential benefit: If successful, this could produce new targeted drugs for patients whose tumors depend on NSD3, especially those with lung squamous cell carcinoma.
How similar studies have performed: High-throughput screening has produced therapies targeting other histone-modifying enzymes, but specific NSD3 inhibitors have not been reported before, so this is a novel yet plausible approach.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Grembecka, Jolanta — University of Michigan at Ann Arbor
- Study coordinator: Grembecka, Jolanta
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.